Distek Awarded U.S. Patent 8,903,673
News Feb 24, 2015
Distek, Inc. has been awarded U.S. Patent 8,903,673 for their modularity design and the individual position software control.
Distek’s patented, self-contained, modularity design is configurable for up to 8 positions when in use on the symphony 7100 “Bathless” Dissolution Instrument and 6 positions when in use on thesensIR 3200 “Bathless” Disintegrator. This modularity design allows users unprecedented ease and scalability.
“Distek is excited to have been awarded this patent which exemplifies our commitment to providing technically innovative products offering valuable feature benefits to our customer base,” says Jeff Brinker, President, Distek, Inc.
Brinker continued, “This patent in particular allows our customers a great deal of flexibility in the symphony 7100 and sensIR 3200 platforms in its modularity both mechanically as well as in the user interface design.”
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Antibody Drug-Conjugate to Target Treatment-Resistant Childhood LeukemiaNews
Researchers have discovered that a protein (5T4) found on the surface of cells contributes to chemotherapy resistance in the most common type of childhood leukaemia. Using a novel approach, early testing shows that targeting the protein with an antibody drug conjugate (ADC) could hold promise in improving treatment.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018